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homeostasis is abnormal in cystic fibrosis (CF). Concentrations
of iron in the sputum and bronchoalveolar lavage (BAL) fluid
of healthy unaffected persons are b16 μmol/l [1,2] and
0.13 μmol/l [3], respectively, whereas that of CF sputum
generally exceeds 30 μmol/l and can be as high as 200 μmol/l
[1,2]. Using an in-vitro co-culture model of polarized human
bronchial epithelial cells and Pseudomonas aeruginosa (Pa),
Moreau-Marquis et al. [4] first observed that F508del-CFTR
increased the iron content of airway surface liquid, a
phenomenon that promoted Pa biofilm growth. Thus, the
genetic defect found in most CF patients [5] plausibly
contributes to the persistence of this and other pathogens by
increasing the availability of a typically scarce micronutrient.
Among CF adults, those who have more iron in their sputum
not only have higher circulating interleukin-6 (IL-6) levels
but also have lower blood iron stores, or relative hypoferremia [6].
IL-6 drives hepatic production of the small peptide hormone,
hepcidin-25, which potently induces hypoferremia [7].
I am intrigued by the observations of Uijterschout et al. [8] that
serum hepcidin-25 levels were generally low in children with
CF but were higher among those who recently experienced a
pulmonary exacerbation than those who displayed stable health.
These data in the pediatric CF population, coupled with those
presented by Gifford et al. in CF adults [9], highlight the central
regulatory role of hepcidin-25 in iron handling, particularly as the
inflammatory milieu waxes and wanes in these patients with
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objective evidence for the presence or absence of pulmonary
exacerbations, symptomatic periods in the natural history
of CF [10] for which definitions are still debated [11,12].
Uijterschout et al. [8] classified acute assessments as those
during which children were found to have an elevated serum
C-reactive protein (CRP) N10 mg/l and a history within the prior
month of clinical deterioration and/or decrease in pulmonary
function requiring antibiotics. In addition to having a mean
serum hepcidin-25 level nearly three times higher than that
of 36 stable children, the cohort of 13 acute patients had
significantly worse pulmonary function and was older and more
commonly infected by Pa. In 12 adults who met published
criteria for pulmonary exacerbation [6], Gifford et al. [9] fund that
serum IL-6 and hepcidin-25 fell commensurately in response
to intravenous antibiotics. Interestingly, the mean post-treatment
serum hepcidin-25 concentration for these CF adults (22.7 ng/ml)
exceeded that reported by Uijterschout et al. [8] for their acute
(14.5 ng/ml) and stable (5.0 ng/ml) pediatric patients, applying a
conversion factor for serum hepcidin of 1 nM = 2.79 μg/l.
This comparison suggests that hepcidin-25 production might
increase across the lifespan of CF patients, perhaps due to
stimulation of the liver by IL-6 and/or other cytokines or by
exposure to cryptic microbial factors. Alternatively, CF hepato-
cytes may lose their ability to appropriately restrict hepcidin-25
synthesis in light of hypoxemia or erythropoietic stimuli [13].
Progressive iron accumulation in the CF lung [14] might also
convey an erroneous signal of iron sufficiency or even overload to
the liver, which would be predicted to raise hepcidin-25 levels.
Small peptides with internal disulfide bonds, including hepcidin-25
[15], have intrinsic antimicrobial properties, raising the possibility
that higher serum concentrations in adults reflect an augmentationll rights reserved.
Table 1
Heterogeneity in the biochemical definition of iron deficiency in cystic fibrosis. TSAT = transferrin saturation; sTfR = soluble transferrin receptor.
Prevalence Serum Fe TSAT Ferritin sTfR Hepcidin-25
Adults None
Gifford et al. [16] 100% ≤21%
Gifford et al. [9] 83% b12 μmol/l
Gifford et al. [6] 64% (stable)
100% (acute)
b12 μmol/l






b15% ≤12 μg/l d
≤20 μg/l e
N1.74 mg/l
Reid et al. [19] 74% ≤12 μmol/l ≤16%
Keevil et al. [20] b 15% N 1.74 mg/l
Pond et al. [21] 62% b16%
Children
Uijterschout et al. [8] 14% b12 μg/l f
b15 μg/l g
Uijterschout et al. [17] 60% b12 μg/l f
b15 μg/l g
Ehrhardt et al. [22] 53%h b12 μg/l






f Children b5 years of age.
g Children N5 years of age.
h Among patients b16 years of age.
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and/or virulent than those usually found in the pediatric CF lung.
Studies designed to track the evolution of hepcidin biochemistry
within the same patients stand to generate important knowledge
about CF iron homeostasis.
Given that hepcidin-25 induces hypoferremia by attenuating
duodenal iron absorption and promoting iron sequestration in
mononuclear cells [13], it is reasonable to posit that differences
in the prevalence of hypoferremia between children and adults
with CF (Table 1) are explained by differences in circulating
hepcidin-25 levels, and by extension, differences in acute
and chronic health status. Indeed, Gifford et al. [16] recently
demonstrated in a longitudinal study of 22 adults with advanced
disease that serum hepcidin-25 measurements were directly
correlated with Akron Pulmonary Exacerbation Scores. There-
fore, while context-specific variation in serum hepcidin-25 could
limit its utility as diagnostic test for iron deficiency, changes that
are stereotypical for a given patient may prove useful in the
prediction of clinical events and/or treatment adequacy.
From a practical standpoint, iron status is a moving target in CF.
As Uijterschout et al. [8] discovered for soluble transferrin receptor
(sTfR), a single blood test is unlikely to distinguish between
absolute and functional iron deficiency in the CF population,
especially when numerous biochemical criteria (Table 1) have
been used to describe these entities. Nonetheless, their use of serum
ferritin b12 μg/l in children b5 years of age and b15 μg/l in older
children to define iron deficiency is certainly sound and consistent
with earlier work [17], adding an invaluable measure of uniformityto the pediatric literature on this topic. Arbitrarily determining
cutoffs for various iron-related hematologic parameters, even
serum hepcidin-25, may not be the most constructive approach to
understanding CF iron homeostasis. Rather, the CF community
should work toward consensus about the measurement, interpre-
tation, and use of these parameters in clinical practice.
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